Results 61 to 70 of about 1,295 (151)

Minimising the Dosage-Limiting Toxicities of Foscarnet Induction Therapy

, 1997
This article suggests ways to manage the dose-limiting adverse reactions caused by foscarnet so that this agent may be used with confidence as first-line therapy in patients with cytomegalovirus (CMV) disease.Foscarnet (trisodium phosphonoformate) has ...
Jayaweera, Dushyantha
core   +1 more source

Maribavir for Cytomegalovirus Infection in High‐Risk Kidney Transplant Recipients: A Case Series

IJU Case Reports, Volume 9, Issue 3, May 2026.
ABSTRACT Background Cytomegalovirus (CMV) infection remains a common complication after kidney transplantation, particularly among high‐risk donor‐seropositive/recipient‐seronegative (D+/R−) recipients. Valganciclovir is the standard first‐line therapy; however, its use may be limited by hematological toxicity or impaired graft function. Maribavir is a
Daiji Takamoto, Yu Shimada, Yuri Hasegawa, Takeaki Noguchi, Takashi Kawahara, Junichi Teranishi, Kazuhide Makiyama   +6 more
wiley   +1 more source

Real-World Comparison of Maribavir to Foscarnet for the Treatment of Cytomegalovirus in Solid Organ and Hematopoietic Stem Cell Transplant Recipients

Viruses
Cytomegalovirus (CMV) infection in solid organ transplant (SOT) and hematopoietic cell transplant (HCT) recipients may increase the risk of rejection or allograft dysfunction, other infection(s), and morbidity and mortality.
Lauren Ogawa, Chelsea Morinishi, Ashrit Multani, Pryce Gaynor, Omer E. Beaird, Christine Pham, Joanna M. Schaenman   +6 more
doaj   +1 more source

Use of Foscarnet Therapy for EBV Infection following Control of PTLD with Enhancement of Cellular Immunity in a Lung-Transplant Recipient

Journal of Transplantation, 2011
Posttransplant lymphoproliferative disorder (PTLD) is a serious complication following solid organ transplantation with an annual incidence rate of 3–5% in lung-transplant recipients.
Kamyar Afshar, A. Purush Rao, Vipul Patel, Kevin Forrester, Sivagini Ganesh   +4 more
doaj   +1 more source

Human Cytomegalovirus Infection in Haematopoietic Stem Cell Transplant Recipients and CAR‐T Cell Recipients—PART 2: Antiviral Therapy and Virus‐Specific T Cell Therapy for HCMV in Allo‐HSCT

Reviews in Medical Virology, Volume 36, Issue 3, May 2026.
ABSTRACT Human cytomegalovirus (HCMV) reactivation is a common and significant complication after allogeneic haematopoietic stem cell transplantation (allo‐HSCT), causing potentially life‐threatening disease. Antiviral therapy approaches for HCMV are often limited by toxicities and the risk of developing antiviral drug resistance.
Gaurav Sutrave, Michelle K. Yong, Danya Kaplan, David J. Gottlieb, Allison Abendroth, Barry Slobedman, Emily Blyth, Lauren Stern   +7 more
wiley   +1 more source

In Vivo Emergence of UL56 C325Y Cytomegalovirus Resistance to Letermovir in a Patient with Acute Myeloid Leukemia after Hematopoietic Cell Transplantation

Mediterranean Journal of Hematology and Infectious Diseases, 2019
CMV associated tissue-invasive disease is associated with a considerable risk of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (HSCT). Recently, the terminase inhibitor letermovir (LMV) has been approved for prophylaxis
Jochen J Frietsch, Detlef Michel, Thomas Stamminger, Friederike Hunstig, Sebastian Birndt, Ulf Schnetzke, Sebastian Scholl, Andreas Hochhaus, Inken Hilgendorf   +8 more
doaj   +1 more source

Foscarnet calcium microcrystals as the intravitreal drug depot

, 2017
Injectable foscarnet calcium microcrystals can maintain the intravitreal drug concentration for months.
Yuling Sun, Yanbin Huang, Yong Tao, Qingchen Cao   +3 more
core   +1 more source

Effect of foscarnet therapy on human immunodeficiency virus p24 antigen levels in aids patients with cytomegalovirus retinitis

, 1992
Circulating human immunodeficiency virus (HIV) p24 antigen levels were measured in 22 AIDS patients who had detectable serum antigen at baseline after induction and maintenance therapy of foscarnet for cytomegalovirus retinitis in phase I/II multicenter ...
G. F. McKinley, C. M. van der Horst, R. B. Davis, McKinley, George F., DAVIS, R. B, M. A. Jacobson, HOOTON, T. M, Parenti, David M., VAN DER HORST, C. M, JACOBSON, M. A, M. M. Reddy, Grieco, Michael H., Reddy, Mohan M., CAUSEY, D. M, Davis, Roger B., Causey, Dennis M., Hooton, Thomas M., PARENTI, D. M, Jacobson, Mark A., D. M. Parenti, D. M. Causey, MCKINLEY, G. F, T. M. Hooton, REDDY, M. M, van der Horst Charles, M., GRIECO, M. H, M. H. Grieco   +26 more
core   +1 more source

Overcoming Resistance: A Comprehensive Review and Treatment Approach for Acyclovir-Resistant Herpes Simplex Keratitis

Journal of Current Ophthalmology
Purpose: To comprehensively review the treatment approach for acyclovir (ACV)-resistant herpes simplex keratitis (HSK). Methods: We thoroughly searched Web of Science, PubMed, and Scopus for relevant keywords and conducted this narrative review which ...
Arash Mirzaei, Sahel Soltani Shahgoli, Raghuram Kognati, Emine Esra Karaca, Kasra Cheraqpour, Farhaneh Alahyari, Deepak Shukla, Ali R. Djalilian, Mohammad Soleimani   +8 more
doaj   +1 more source

Cytomegalovirus infection in pediatric haploidentical stem cell transplantation

Hematology/Oncology and Stem Cell Therapy
Background: Human cytomegalovirus (CMV) is a major source of morbidity and mortality in pediatric hematopoietic stem cell transplantation (HSCT). CMV replication is mainly controlled by T-cell-mediated immunity.
Abdulrahman AlSweed, Suliman Aljumaah, Hawazen AlSaedi, Hibah Alruwaisan, Raghad Alhuthil, Sami Al-Hajjar   +5 more
doaj   +1 more source